Drug Profile
Research programme: cannabinoid-based therapeutics - Revive Therapeutics
Alternative Names: REV 100; REV 101; REV 200; REV 201Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Revive Therapeutics
- Developer Revive Therapeutics; University of Wisconsin-Madison
- Class Analgesics; Anti-inflammatories; Antipsoriatics; Cannabinoids; Hepatoprotectants; Skin disorder therapies; Small molecules
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acne; Autoimmune hepatitis; Dermatitis; Kidney disorders; Liver disorders; Neuropathic pain; Non-alcoholic steatohepatitis; Psoriasis; Wounds
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for research development in Liver-disorders in Canada
- 28 Jul 2022 No recent reports of development identified for preclinical development in Autoimmune-hepatitis in Canada
- 28 Jul 2022 No recent reports of development identified for preclinical development in Dermatitis in Canada (Topical)